

Explicit™ Evidence-based Clinical Practice Guideline Resource Kit – Irritable Bowel Syndrome (IBS)

This kit contains information about the best available evidence on IBS diagnosis and treatment to assist you and your patients in making testing and care management decisions. Tools and tips are also included.

Our Approach (See the Guideline Documentation in **Guideline Resource Information** for details)

Our approach emphasizes evidence and patient-centered care. We used an “explicit” evidence-based methodology based on the principles and systematic methods for guideline development first conceptualized by David Eddy, MD, PhD, and operationalized by Michael Stuart, MD, during his career at Group Health Cooperative – a consumer-owned health care system in Washington State, renown for its quality care. This work was sponsored and funded by Novartis. Our approach to this work was to apply the same high and identical standards we apply to all our work and was modeled on prior work done without industry support.

Who We Are

Delfini Group, LLC is devoted to assisting others learn how to apply evidence- and value-based medicine principles in an easy-to-understand way through training, consultations, resources and tools. Detailed information about us is available at www.delfini.org where you can also access the guideline.

Guideline Resource Kit Contents – March 2003; Herbal Preparations 07/06; Medication Withdrawal 04/07; Rome III Criteria 06/09

- ♦ **Explicit™ Evidence Based Clinical Practice Guideline Resource Information:** Guideline materials designed primarily for primary care physicians and other clinicians who diagnose and manage IBS in adult patients and for professionals who plan and implement clinical quality improvement projects. These materials may be useful “as is” or may be helpful as “seeds” for creating information and decision aids that meet local needs.
- ♦ **Information & Decision Aid for Adult Patients and Practitioners:** Decision support including information and resources on IBS, treatment options, drug risks and benefits, and general information about evidence-based medicine
- ♦ **Systematic Review Summaries:** Critical appraisals of key scientific work used in developing the guideline materials
- ♦ **Implementation and Communication Tool:** Ideas and tips for clinical practice change
- ♦ **Impact Assessment Template:** Spreadsheet template included as an optional, customizable aid designed to help health care organizations project potential changes which may result from successful guideline implementation. A completed tool is included as an example and was constructed using assumptions generated through meetings with national medical leaders.

Acknowledgements

We extend special thanks to Novartis Pharmaceutical Corporation for support and sponsorship, Assistant Director, APO Marketing; our colleagues at EBMed – especially David Bjorkman, MD, MSPH (HSA), SM (Epid); Walter Peterson, MD; Debra Palestina, Executive Director; and Lyn Bowen, Project Manager; and Fanizzi Associates, especially Patti Robinson, Senior Project Manager and Kate Brown, Meeting Planner.

